FDMT Q4 2021 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92,000+109.4% YoY

Gross Profit

-$17M-18952.2% margin

Operating Income

-$25M-26917.4% margin

Net Income

-$25M-27264.1% margin

EPS (Diluted)

$-0.93

QoQ Revenue Growth

-93.3%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$353M

Total Liabilities

$34M

Stockholders' Equity

$319M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92,000	-$977,000	+109.4%
Gross Profit	-$17M	-$14M	-28.4%
Operating Income	-$25M	-$20M	-21.3%
Net Income	-$25M	-$21M	-22.1%

Geographic Segments

UNITED STATES

$89,00088%

NETHERLANDS

$12,00012%